106 related articles for article (PubMed ID: 32567541)
1. An examination of multiple explanations for secondary hyperparathyroidism
.
Phelps KR; Mason DL
Clin Nephrol; 2020 Aug; 94(2):70-77. PubMed ID: 32567541
[TBL] [Abstract][Full Text] [Related]
2. Tradeoff-in-the-Nephron: A Theory to Explain the Primacy of Phosphate in the Pathogenesis of Secondary Hyperparathyroidism.
Phelps KR
Nutrients; 2017 Apr; 9(5):. PubMed ID: 28445401
[TBL] [Abstract][Full Text] [Related]
3. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
Phelps KR; Stote KS; Mason D
Clin Nephrol; 2014 Sep; 82(3):191-201. PubMed ID: 25079864
[TBL] [Abstract][Full Text] [Related]
4. Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism.
Phelps KR; Gemoets DE; May PM
PLoS One; 2022; 17(8):e0272380. PubMed ID: 35913960
[TBL] [Abstract][Full Text] [Related]
5. Phosphate homeostasis, parathyroid hormone, and fibroblast growth factor 23 in stages 3 and 4 chronic kidney disease.
Phelps KR; Mason DL; Stote KS
Clin Nephrol; 2016 May; 85(5):251-61. PubMed ID: 26951967
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption.
Phelps KR; Mason DL
Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023
[TBL] [Abstract][Full Text] [Related]
7. Tubular calcium reabsorption and other aspects of calcium homeostasis in primary and secondary hyperparathyroidism.
Phelps KR; Stote KS; Mason D
Clin Nephrol; 2014 Aug; 82(2):83-91. PubMed ID: 24985952
[TBL] [Abstract][Full Text] [Related]
8. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
Ennis JL; Worcester EM; Coe FL; Sprague SM
J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
[TBL] [Abstract][Full Text] [Related]
9. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
[TBL] [Abstract][Full Text] [Related]
10. Elderly patients with chronic kidney disease have higher risk of hyperparathyroidism.
Elias RM; Moysés RMA
Int Urol Nephrol; 2017 Oct; 49(10):1815-1821. PubMed ID: 28695313
[TBL] [Abstract][Full Text] [Related]
11. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
12. Influence of Pre-renal Transplant Secondary Hyperparathyroidism on Later Evolution After Transplantation.
Garcia-Montemayor V; Sánchez-Agesta M; Agüera ML; Calle Ó; Navarro MD; Rodríguez A; Aljama P
Transplant Proc; 2019 Mar; 51(2):344-349. PubMed ID: 30879538
[TBL] [Abstract][Full Text] [Related]
13. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.
Pitts TO; Piraino BH; Mitro R; Chen TC; Segre GV; Greenberg A; Puschett JB
J Clin Endocrinol Metab; 1988 Nov; 67(5):876-81. PubMed ID: 3182962
[TBL] [Abstract][Full Text] [Related]
14. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
[TBL] [Abstract][Full Text] [Related]
15. Serum vitamin D in obese and overweight subjects according to estimated glomerular filtration rate.
Kitsos A; Dounousi E; Kalaitzidis R; Challa A; Siamopoulos KC; Tigas S
Hormones (Athens); 2018 Jun; 17(2):237-246. PubMed ID: 29858844
[TBL] [Abstract][Full Text] [Related]
16. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.
Sprague SM; Crawford PW; Melnick JZ; Strugnell SA; Ali S; Mangoo-Karim R; Lee S; Petkovich PM; Bishop CW
Am J Nephrol; 2016; 44(4):316-325. PubMed ID: 27676085
[TBL] [Abstract][Full Text] [Related]
17. Determinants of the serum phosphate concentration in chronic kidney disease.
Gosmanova EO; Gemoets DE; Dharia S; Der Mesropian P; Shaikh G; Kovesdy CP; Phelps KR
Clin Nephrol; 2024 Feb; 101(2):82-92. PubMed ID: 38085074
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
Kuczera P; Adamczak M; Wiecek A
Clin Endocrinol (Oxf); 2014 Apr; 80(4):607-12. PubMed ID: 24111496
[TBL] [Abstract][Full Text] [Related]
19. Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients.
Boudville NC; Hodsman AB
Nephrol Dial Transplant; 2006 Sep; 21(9):2621-4. PubMed ID: 16644777
[TBL] [Abstract][Full Text] [Related]
20. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A
Nephron; 2018; 139(4):286-292. PubMed ID: 29879701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
